AVI BioPharma, Inc. (NASDAQ:AVII)

CAPS Rating: 4 out of 5

A biopharmaceutical company developing therapeutic products principally based on third-generation NEUGENE antisense technology.

Recs

0
Player Avatar neilepi (< 20) Submitted: 2/4/2012 12:03:00 PM : Outperform Start Price: $1.02 AVII Score: -28.16

Good reports, low valuation

Report this Post Reply

Featured Broker Partners


Advertisement